JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/14/2026

1. ORCL
2. NVDA
3. SPY
4. DFTX
5. AZN
6. SATL
7. SRRK
8. LYNX
9. BBNX
10. USO

Go back to JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis
(NASDAQ: ROIV) Delayed: 40.89 +0.07 (0.17%)
Previous Close $40.82    52 Week High $ 
Open $40.64    52 Week Low $ 
Day High $41.33    P/E N/A 
Day Low $40.44    EPS $ 
Volume 508,740       

(NASDAQ: ROIVW) Delayed: 2.75 --0 (-0%)
Previous Close $2.75    52 Week High $ 
Open $25.55    52 Week Low $ 
Day High $2.75    P/E N/A 
Day Low $2.75    EPS $ 
Volume 555